• Background: Currently, less frequent than once-weekly subcutaneous epoetin administration regimens were shown to be equally effective and safe as once-weekly schedules in stable predialysis and peritoneal dialysis patients. Bioequivalency of once-every-2-weeks and once-weekly subcutaneous administration of the same total dose of epoetin beta for the maintenance phase of anemia treatment in stable iron-replete long-term hemodialysis patients therefore was investigated prospectively. Methods: Two hundred seven stable selected hemodialysis patients without diabetes, acute illness, significant inflammation, malnutrition or hyperparathyroidism administered once-weekly subcutaneous epoetin beta and preserving stable hemoglobin levels between 10 and 12 g/dL (100 and 120 g/L; difference between maximum and minimum of 3 subsequent levels <2.5 g/dL [<25 g/L]) and optimal iron status for at least 8 weeks before inclusion were enrolled and randomly assigned to subcutaneous administration of the same total dose of epoetin beta either once every 2 weeks (group 2w; n ‫؍‬ 104) or once weekly (group 1w; n ‫؍‬ 103) for 24 weeks. Results: Per-protocol analyses (group 1w ‫؍‬ 102 versus group 2w ‫؍‬ 101) showed similar hemoglobin levels throughout the assessment period (weeks 13 to 24): mean, 11.38 g/dL; 95% confidence interval (CI), 11.23 to 11.54 versus 11.41 g/dL; 95% CI, 11.22 to 11.58. Mean difference was 0.028 g/dL (95% CI, ؊0.208 to 0.264) in the prespecified range (؎0.5 g/dL). Epoetin dose ratio of group 2w to group 1w was 0.94 (95% CI, 0.813 to 1.076), also in the prespecified range of equivalence (0.80 to 1.25). Hemoglobin levels and epoetin doses were stable during the study irrespective of treatment schedule, with no differences between groups at any time. Both schedules were well tolerated. Conclusion: Once-every-2-weeks and once-weekly subcutaneous epoetin beta regimens are equivalent in the maintenance phase of anemia treatment in long-term stable hemodialysis patients without diabetes, with similar safety profiles. Am J Kidney Dis 48:445-455.
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C
URRENT EUROPEAN Best Practice Guidelines 1,2 and the Kidney Disease Outcomes Quality Initiative Committee in the United States 3 recommend preferential subcutaneous (SC) twice-to thrice-weekly epoetin administration. The SC route significantly decreases epoetin requirements and therefore costs compared with the intravenous (IV) route. [4] [5] [6] In addition, solid evidence shows that once-weekly SC administration of epoetin beta is equally efficient and well tolerated in hemodialysis (HD) patients. 7, 8 Clinical studies suggested that effects of epoetin alfa are sustained for more than 1 week, enabling less frequent dosing schedules in predialysis patients with chronic kidney disease (CKD).
9,10 A recent European multicenter study of peritoneal dialysis (PD) patients confirmed that once-every-2-weeks SC epoetin beta administration is efficient and safe in the maintenance phase of anemia treatment for PD patients. 11 Thus, the optimum epoetin dosing regimen is still to be determined despite more than a decade of clinical use. All these data also suggest that pharmacodynamic effects of epoetins could last longer than their plasma half-lives. The survival half-life of erythrocytes produced after exogenous epoetin administration is longer than that of erythrocytes produced in the absence of exogenous stimulation. 12, 13 Apart from the academic interest, this issue has direct implications on cost savings and increased patient convenience. Furthermore, less frequent administration would decrease epidemiological hazards associated with populations at high risk for such blood-borne viral infections as hepatitis, particularly important in less developed countries with a high prevalence of viral hepatitis infections (hepatitis B and C markers prevalences, 15 .7% and 45% in Romania versus 3% and 13.5% in patients from the 5 European countries participating in the Dialysis Outcomes and Practice Patterns Study, respectively). [14] [15] [16] Although the potential benefits of less frequent dosing are clear, the efficacy and safety of such regimens must be investigated fully before adoption as standard treatment.
The present study investigates for the first time the equivalence of once-weekly versus onceevery-2-weeks SC epoetin beta dosing regimens in the maintenance phase of anemia therapy in stable HD patients. The aim of the study is to assess whether once-every-other-week SC administration of the same total epoetin beta dose is as effective and as safe as SC once-weekly dosing.
METHODS

Study Design
This is a multicenter, prospective, open-label, parallel, randomized controlled trial of therapy equivalence. Total observation time was 32 weeks. Eligible patients gave informed consent and entered an 8-week baseline phase. At the end of this phase, subjects were centrally randomized (1:1 ratio) to administration of epoetin beta once every other week (group 2w) or to continue the previous once-weekly regimen (group 1w). Randomization was performed by the Romanian Renal Registry based on numbered containers. The 24-week study phase consisted of a 12-week run-in period and a 12-week assessment period.
The trial is designed according to guidelines for studies testing the equivalence of different treatment regimens 17 and was conducted with provisions of the Declaration of Helsinki and Tokyo as amended in Venice (1983) . The protocol was approved by the local Hospital Ethics Committee, as well as by the National Ethics Committee and National Medicines Agency.
Selection Criteria
Inclusion and exclusion criteria were evaluated at enrollment, after 4 weeks, and at randomization.
Inclusion criteria. Inclusion criteria were adults (age Ն 18 years), at least 6 months on efficient HD therapy (ureaequilibrated Kt/V Ն 1.2, Daugirdas II equation), hemoglobin (Hb) levels greater than the Romanian recommended target of 10 g/dL (100 g/L)
18 and stable (difference between maximum and minimum values at 3 subsequent determinations Յ 2.5 g/dL [Յ25 g/L]), with adequate iron status (serum ferritin level, 100 to 800 ng/mL [100 to 800 g/L]) and transferrin saturation (20% to 50%). 1, 2 All eligible patients had to be administered once-weekly SC epoetin beta for at least 2 months before enrollment.
Exclusion criteria. Patients with cardiac failure or hepatic diseases (defined as abnormal alanine aminotransferase and aspartate aminotransferase levels), significant inflammation (C-reactive protein [CRP] level Ͼ 12 mg/L), 19 severe hyperparathyroidism (intact parathyroid hormone level Ͼ 800 pg/mL [Ͼ800 ng/mL]), 20 history of gastrointestinal bleeding, greater than 5% variation in dry body weight in the last 6 months, previously diagnosed folic acid and/or vitamin B 12 deficiency, poor blood pressure control (blood pressure, measured before the dialysis session while sitting after 10 minutes of rest, Ն 140/90 mm Hg despite antihypertensive medication and fluid control by dialysis), malnutrition (Subjective Global Assessment score B or C and/or serum albumin level Ͻ 4 g/dL [Ͻ40 g/L]), 19 or need for blood transfusions within 2 months before enrollment were excluded.
Therapeutic Intervention
Epoetin beta (NeoRecormon; Hoffmann-La Roche, Basel, Switzerland) was injected SC into the thigh or abdominal area according to patient's prior experience. The injection site was not changed throughout the study.
Dosing frequency. Dosing frequency differed according to the study group. Group 1w continued the previous onceweekly schedule, whereas subjects in group 2w were switched to once-every-other-week administration of the same cumulative dose.
Dose adjustments. The first epoetin dose adjustment was allowed 2 weeks after randomization. Dose adjustments were made every 4 weeks thereafter, depending on Hb level. The most recent Hb value was always compared with the average of the previous 3 determinations. A 20% increase in dose was required if Hb level was less than 10.0 g/dL (Ͻ100.0 g/L) and/or had decreased by more than 1.0 g/dL (10.0 g/L). If Hb level became less than 9.0 g/dL (Ͻ90.0 g/L) and/or decreased by more than 2 g/dL (20.0 g/L), a 50% dose increase was allowed. Similarly, epoetin beta dose was decreased by 20% if Hb level exceeded 13.0 g/dL (Ͼ130.0 g/L) and/or increased by more than 1.0 g/dL (10.0 g/L). A 50% dose reduction was permitted for Hb levels exceeding 14.0 g/dL (Ͼ140.0 g/L) and/or increasing by more than 2.0 g/dL (20.0 g/L) compared with the reference value. If required, doses were adjusted in the middle of the dosing week succeeding the out-of-range Hb value.
The schedule for iron therapy was continued according to the Romanian Best Practice Guidelines for the Treatment of Anaemia. 18 Patients with serum ferritin levels less than 200 ng/mL (Ͻ200 g/L) were administered 100 mg of IV iron sucrose (Venofer; Vifor, St Galen, Switzerland) weekly. A dose of 100 mg of IV iron sucrose was administered every other week to patients with serum ferritin levels of 200 to 400 ng/mL (200 to 400 g/L) and monthly for serum ferritin levels of 400 to 500 ng/mL (400 to 500 g/L). Iron administration was stopped if serum ferritin levels exceeded 500 ng/mL. Oral iron supplementation was not allowed in the study.
Parameters
Hb level and weekly epoetin beta dose per dry body weight in the assessment period (average of all values from weeks 13 to 24) were set as primary efficacy parameters. In group 2w, weekly epoetin dose was obtained by halving the dose administered every other week.
Secondary efficacy parameters were the percentage of patients maintaining target Hb levels without an increase in epoetin dose during the assessment period, the difference between average Hb levels during the assessment period versus baseline phase, and the difference between average weekly epoetin beta doses during the assessment period versus baseline phase. Iron status (serum ferritin level, transferrin saturation) and iron supplementation (percentage of patients receiving iron therapy, cumulative iron dose per week per treated patient) also were assessed.
Blood pressure levels; drug therapy requirements for hypertension; heparin dose; occurrence of adverse events, including thrombosis; and number of withdrawals were safety variables.
Monitoring Schedule
Ten blood samplings were scheduled for each patient, to be drawn before the midweek dialysis session during weeks Ϫ8, Ϫ4, 0, 2, 4, 8, 12, 16, 20, and 24. Laboratory reports included Hb, complete blood cell count, iron status, CRP, serum albumin, and safety biochemical parameters (serum sodium, potassium, calcium, phosphate, liver enzymes, alkaline phosphatase, and bilirubin). Parathyroid hormone level was assessed at enrollment, randomization, and end of the study.
Data Analysis
To avoid a carry-over effect of the weekly schedule of epoetin treatment received before randomization, we defined a run-in period (weeks 1 to 12). Statistical analyses were performed for efficacy parameters determined during the assessment period only. The average for weeks 13 to 24 was obtained by adding all values and dividing the sum by the number of time points for each patient during this period.
The 2 treatment schedules were considered equivalent if the primary efficacy parameters were simultaneously similar for both groups and in the predefined range of variation. Confidence intervals (CIs) were used to compare groups. Because target Hb level in dialysis patients is defined as 11 g/dL (110 g/L) by the European Guidelines 1,2 and greater than 10 g/dL (Ͼ100 g/L) by the National Guidelines, 18 with a recommended upper limit of 13 g/dL (130 g/L), 1,2,18 the efficacy range for Hb levels in this study was predefined as 10 to 12 g/dL (100 to 120 g/L). The 2 treatment schedules were considered to have similar efficacy if mean Hb level in group 2w did not differ by more than Ϯ0.5 g/dL (Ϯ5 g/L) compared with group 1w during the assessment period. When similar efficacy was established, drug requirements were compared by calculating the mean weekly epoetin dose ratio in group 2w to group 1w. A range of 0.8 to 1.25 for the ratio is considered sufficient to define bioequivalence. 17 Equivalence of drug use in the 2 arms was accepted if the entire 95% CI for this ratio was within these limits.
Lack of difference between group means does not imply similar distribution of treatment effects within each group. Individual Hb level change was used to assess whether the response to treatment was similarly variable in the 2 arms. Change in Hb level was calculated for each patient as the difference between mean Hb level during the assessment period and mean Hb level during the baseline phase. Percentages of patients with target Hb levels not requiring an increase in epoetin dose during the assessment period were compared by means of chi-squared statistic.
The study is designed to detect a difference in Hb levels between study groups of at least 0.5 g/dL (5 g/L), with a probability of 95% and power of 0.90, 21 assuming an SD of Hb level in the HD population of 1.0 g/dL (10 g/L). A sample size of 85 patients was required in each arm of the trial. Because the study design included epoetin dose variations to maintain target Hb levels, it would be expected that Hb levels would be constant and epoetin dose would vary. Therefore, power calculations using epoetin doses as the outcome measure seemed to be more appropriate. Considering an SD of 39 IU/kg/wk, probability of 95%, and power of 90%, a sample size of 70 patients in each arm would be required to detect a Ϯ20% difference in epoetin dose between groups. Because of an anticipated dropout proportion of 15%, a minimum of 100 patients had to be enrolled in each group to satisfy both Hb level and epoetin dose power conditions.
Only patients who fulfilled all selection criteria and completed the study were included in statistical analyses. 17 Data are presented as mean Ϯ SD for parameters with normal distribution or median and interquartile range for skewed data. Interval estimates of differences between treatment groups were calculated as 95% CI for the mean, mean difference, or mean ratio. Student t-test, chi-square, and nonparametric tests were used to determine statistical significant differences in baseline parameters between study groups.
RESULTS
Two hundred seven adult HD patients without diabetes from 9 Romanian centers were enrolled between March 1, 2004 , and January 31, 2005. Four patients did not complete the study. Two patients from group 1w withdrew for personal reasons. One patient in group 2w was lost to follow-up, and another patient was excluded because of a major surgical procedure.
The remaining 203 patients were included in the statistical analysis sample (101 in group 1w and 102 in group 2w; Fig 1) .
Patient characteristics at baseline are listed in Table 1 . Enrolled patients were selected to have simultaneously stable hematologic and iron status in the target range. Overall, the study population was younger, did not have diabetes, had lower CRP levels (per exclusion criteria, see Methods), and were administered lower epoetin weekly doses compared with the overall prevalent Romanian dialysis population.
14 Of note, there were no differences in investigated parameters between groups at randomization.
Primary Efficacy Parameters
During the assessment period, mean Hb levels and 95% CIs in group 1w were similar to those in group 2w and in the prespecified range of 10 to 12 g/dL (100 to 120 g/L): 11.38 g/dL (95% CI, 11.23 to 11.54) versus 11.41 g/dL (95% CI, 11.24 to 11.58; [113.8 g/L; 95% CI, 112.3 to 115.4 versus 114.1 g/L; 95% CI, 112.4 to 115.8]). The difference of 0.028 g/dL (95% CI, Ϫ0.21 to 0.26; [0.28 g/L; 95% CI, Ϫ2.1 to 2.6]) in mean values between group 2w and group 1w also was in the prespecified range of Ϯ0.5 g/dL (Ϯ5 g/L).
Mean cumulative epoetin doses per week were similar in the 2 arms: 71.8 UI/kg (95% CI, 65.8 to 77.8) in group 1w versus 67.8 UI/kg (95% CI, 60.3 to 75.3) in group 2w. The ratio of group 2w to group 1w mean cumulative epoetin doses was 0.94, and the 95% CI (0.81 to 1.08) was within prespecified limits.
Secondary Efficacy Parameters
Differences (average of all individual changes from baseline mean to assessment mean) in mean Hb levels and epoetin doses between the assessment period and baseline phase were similar in the 2 arms ( Table 2) .
The proportion of patients maintaining the target Hb level of greater than 10 g/dL (Ͼ100 g/L)
18 without requiring an increase in (epoetin) dose was greater than 60% and did not differ between groups throughout the assessment period (Fig 2) . Considering the European and American recommendations for target Hb levels, 2,3 the percentage of patients maintaining Hb levels greater than 11.0 g/dL (Ͼ110.0 g/L) without an increase in epoetin dose was greater than 50%, without differences between groups at any census point. Furthermore, mean Hb levels were stable in both groups without a significant difference between arms during the study (Fig 3) . Also, mean weekly epoetin dose was stable throughout the study in both groups, and no statistically significant differences between arms were noted (Fig 4) . NOTE. To convert Hb in g/dL to g/L, multiply by 10. *Difference (mean value during assessment period Ϫ mean value during baseline phase). †Ratio (mean dose during assessment period/mean dose during baseline phase).
Iron Status, Inflammation, and Hyperparathyroidism
Throughout the study period, serum ferritin and transferrin saturation values did not differ significantly between groups, and all patients maintained target iron status (Table 3 ). Similar high percentages of patients were administered IV iron: 90% in group 1w versus 85% in group 2w. Mean cumulative iron doses were 53.1 (95% CI, 47.3 to 58.9) and 54.8 mg/wk (95% CI, 45.5 to 64.1) per treated patient in groups 1w and 2w, respectively. The group ratio of mean total iron dose was 1.032 (95% CI, 0.822 to 1.242). Therefore, iron requirements were similar in both arms during the assessment period.
Percentages of patients with inflammation (CRP Ͼ 5 mg/L) 19 and hyperparathyroidism (parathyroid hormone Ͼ 300 pg/mL [Ͼ300 ng/L]) 20 were similar in both arms, without significant variations throughout the study (Table 3) .
Safety Parameters
Safety parameters were analyzed in all enrolled patients. There were no differences between groups in blood pressures, and no requirements for an increase in antihypertensive treatment were noted (Table 4) .
No clinically relevant thrombotic event was recorded. The ratio of mean cumulative heparin dose in group 2w to group 1w was 1.03 (95% CI, 1.00 to 1.07), and no patient in any group required an increase in heparin dose throughout the study (Table 4) .
Even in patients administered the cumulative epoetin dose once every other week, pain at the injection site was not reported.
No relevant changes in laboratory safety parameters (blood cells, serum albumin, phosphates, potassium, liver enzymes, alkaline phosphatase activity, or Kt/V) were noted.
DISCUSSION
Considerable interest currently focuses on extending dosing intervals of erythropoiesis-stimulating agents beyond periods predicted by their serum half-lives. To date, large randomized trials suggested once-weekly epoetin beta administration to be effective and safe for HD patients, maintaining stable Hb levels similar to twice-or thrice-weekly schedules with similar doses. 7, 8 Although the current study and several previous trials extended the evidence of the efficacy of erythropoiesis-stimulating agents through a broader range of dosing frequencies in patients with CKD or PD or HD patients, 8, 22 ,23 few randomized studies assessing epoetin schedules less frequent than once weekly were published (Table 5) . [9] [10] [11] The Retrospective review of Alternate ProcrIt Dosing (RAPID) study included predialysis patients with CKD who had maintained Hb levels at 11 g/dL or greater (Ն110 g/L) for 3 months with SC epoetin alfa administration once every 2, 3, 4, or more than 4 weeks. However, patient cohorts were not equivalent at baseline in number of patients, Hb levels, or iron status. Furthermore, dose adjustments of epoetin alfa were not restricted to a specific protocol. The most common dosing regimen was once every 2 weeks (51% patients). Because the majority of patients (82%) had Hb levels greater than 11.0 g/dL (Ͼ110 g/L) during the study period and mean Hb level range was 11.6 to 12.4 g/dL (116 to 124 g/L) in each dosing group, the investigators concluded that extended epoetin alfa dosing could be effective. Moreover, because patients were selected from 13 sites, the study suggested that epoetin alfa administration at extended intervals is common in nephrology practice in the United States. 9 More recently, results were published from the Prospective Randomized Open-label evaluation NOTE. Values expressed as median (interquartile range), mean Ϯ SD, or percent. To convert serum ferritin in ng/mL to g/L, multiply by 1; parathyroid hormone in pg/mL to ng/L, multiply by 1.
Abbreviation: NA, not assessed.
of epoetin for Maintenance Phase Treatment of patients with anemia due to CKD (PROMPT) trial. This was a prospective trial of predialysis patients with CKD with Hb levels within target range and previously treated with once-weekly SC epoetin alfa. Patients were randomly assigned to administration of the same erythropoiesis-stimulating agent once weekly, once every 2 weeks, once every 3 weeks, or once every 4 weeks. Dose reduction, but not escalation, was permitted. It was a noninferiority trial designed to compare mean final Hb levels in groups with less frequent dosing with the once-weekly group. Final mean Hb levels were greater than 11.0 g/dL (Ͼ110 g/L) for all groups and similar for all dosing schedules. Analyses of data from a modified intent-to-treat population suggested that even once-every-2-weeks and once-monthly dosing schedules were sufficient to maintain target Hb levels. 10 For continuous ambulatory PD patients, a multicenter nonrandomized open-label study compared once-weekly and once-every-2-weeks epoetin beta regimens.
11 Analysis aimed to determine whether these schedules were equivalent to patients' previous schedules in maintaining Hb levels. Because the difference between mean Hb levels at baseline and during weeks 13 to 25 was within the predefined range, equivalence was stated.
The present study is a randomized controlled trial of well-dialyzed HD patients without diabetes with stable iron stores according to current guidelines 1,2,3,18 and no significant comorbidities, malnutrition, or inflammation to test the equivalence of 2 dosing frequency regimens: once weekly versus once every other week, with the same weekly epoetin beta dose. Equivalence was proved by fulfillment of prespecified criteria for Hb levels, as well as epoetin requirements. Similar mean Hb levels for the 2 arms were found, and the difference between groups was within the predefined range. Concurrently, the group ratio of mean weekly cumulative epoetin beta doses was in the predefined range.
Moreover, target Hb levels could be maintained without a significant increase in (epoetin) dose irrespective of dosing frequency. It is worth noting that differences in mean Hb levels and epoetin dose ratio longitudinally evaluated during the baseline phase and assessment period in each group showed no significant variation, further highlighting the equivalency of the 2 regimens (Table 2) .
Our data support sustained pharmacokinetic action of epoetin beta for 14 days, which is far beyond the half-life of 4 to 18 hours after SC administration. It was proposed that the initial serum epoetin peak after a once-weekly dose may be wasted because erythropoietin receptors on bone marrow progenitor cells become saturated and serum epoetin is continually lost until receptors become available again. 24 It is important to note that studies comparing pharmacokinetic profiles of erythropoietin molecules suggested that half-life is related inversely to binding affinity for the receptor. 24 Thus, because epoetin beta has a 4.3-fold greater binding affinity for the erythropoietin receptor compared with darbepoetin alfa, 25 it may be expected to have a more prolonged erythropoietic response than currently acknowledged.
Because subjects in group 2w were administered double epoetin beta doses at twice longer intervals, safety concerns were of paramount importance. Blood pressure levels were stable in None of the study withdrawals was related to dosing regimen. Therefore, once-every-2-weeks SC epoetin beta was well tolerated. The present study must be interpreted within the context of its limitation and strengths. First, the equivalence of epoetin schedules is difficult to test by using such interrelated efficacy parameters as Hb level and epoetin dose. Hb level, the parameter used to decide dose adjustments, is dose dependent. To overcome this difficulty, in the present study, the 2 equivalency criteria were to be met concurrently and in prespecified clinically relevant ranges. The equivalency range for the difference in mean Hb levels was set at Ϯ0.5 g/dL (Ϯ5 g/L), a narrower interval than in previous reports. 11 To compare epoetin doses, we considered the group ratio more clinically relevant, as described by Locatelli et al, 8 and therefore used it as the other equivalency criterion. Second, iron status was stable and iron requirements were similar in both arms. Finally, to avoid possible confounders, patients with significant inflammation, malnutrition, or severe hyperparathyroidism were excluded. Extents of inflammation and hyperparathyroidism did not fluctuate during the study irrespective of group. The major limitation of our data is related to the younger age of this East European HD population and the lower prevalence of diabetic or vascular kidney disease, features encountered less frequently in typical Western dialysis populations. 14, 26, 27 Our patients also were administered lower epoetin doses than usually reported because of both the lower target Hb level and better iron status resulting from the high percentage of patients treated with IV iron. Nevertheless, the careful design and strict prespecified data analysis support the validity of the current results for stable HD patients without significant comorbidities.
This study has a potential economic impact, particularly important for developing countries. Once-every-2-weeks SC epoetin beta administration also could decrease costs. A smaller number of injections would demand fewer syringes and less nursing time, whereas SC administration can provide cost benefits because of a potential 15% to 20% decrease in dose.
2,10 Additionally, decreasing the number of injections by 26 per year means also a lower risk for blood-borne infections, a critical issue in regions with a high prevalence of viral hepatitis. 14, 15 The extent of these implications for patients and health care providers requires further investigation. Nevertheless, benefits argue for every-2-week epoetin beta administration in HD and PD patients and those with CKD.
In summary, data from this randomized controlled trial suggest that switching carefully selected HD patients without diabetes with no evidence of acute illness, inflammation, hyperparathyroidism, or iron deficiency from onceweekly to once-every-2-weeks SC epoetin beta in the maintenance phase of anemia treatment is well tolerated and allows maintaining target Hb levels without dose increments.
In conclusion, results of the present study suggest that once-every-2-weeks and onceweekly SC epoetin beta regimens are statistically equivalent in the maintenance phase of anemia treatment for a target Hb level range of 10 to 12 g/dL (100 to 120 g/L) in long-term stable HD patients without diabetes, consistent with previous findings in PD patients and patients with CKD, with similar safety profiles and potential economic benefits, supporting a positive development in epoetin beta treatment.
